[go: up one dir, main page]
IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0038816.html
   My bibliography  Save this article

Implementing the Global Plan to Stop TB, 2011–2015 – Optimizing Allocations and the Global Fund’s Contribution: A Scenario Projections Study

Author

Listed:
  • Eline L Korenromp
  • Philippe Glaziou
  • Christopher Fitzpatrick
  • Katherine Floyd
  • Mehran Hosseini
  • Mario Raviglione
  • Rifat Atun
  • Brian Williams
Abstract
Background: The Global Plan to Stop TB estimates funding required in low- and middle-income countries to achieve TB control targets set by the Stop TB Partnership within the context of the Millennium Development Goals. We estimate the contribution and impact of Global Fund investments under various scenarios of allocations across interventions and regions. Methodology/Principal Findings: Using Global Plan assumptions on expected cases and mortality, we estimate treatment costs and mortality impact for diagnosis and treatment for drug-sensitive and multidrug-resistant TB (MDR-TB), including antiretroviral treatment (ART) during DOTS for HIV-co-infected patients, for four country groups, overall and for the Global Fund investments. In 2015, China and India account for 24% of funding need, Eastern Europe and Central Asia (EECA) for 33%, sub-Saharan Africa (SSA) for 20%, and other low- and middle-income countries for 24%. Scale-up of MDR-TB treatment, especially in EECA, drives an increasing global TB funding need – an essential investment to contain the mortality burden associated with MDR-TB and future disease costs. Funding needs rise fastest in SSA, reflecting increasing coverage need of improved TB/HIV management, which saves most lives per dollar spent in the short term. The Global Fund is expected to finance 8–12% of Global Plan implementation costs annually. Lives saved through Global Fund TB support within the available funding envelope could increase 37% if allocations shifted from current regional demand patterns to a prioritized scale-up of improved TB/HIV treatment and secondly DOTS, both mainly in Africa − with EECA region, which has disproportionately high per-patient costs, funded from alternative resources. Conclusions/Significance: These findings, alongside country funding gaps, domestic funding and implementation capacity and equity considerations, should inform strategies and policies for international donors, national governments and disease control programs to implement a more optimal investment approach focusing on highest-impact populations and interventions.

Suggested Citation

  • Eline L Korenromp & Philippe Glaziou & Christopher Fitzpatrick & Katherine Floyd & Mehran Hosseini & Mario Raviglione & Rifat Atun & Brian Williams, 2012. "Implementing the Global Plan to Stop TB, 2011–2015 – Optimizing Allocations and the Global Fund’s Contribution: A Scenario Projections Study," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-10, June.
    • Handle: RePEc:plo:pone00:0038816
    DOI: 10.1371/journal.pone.0038816
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038816
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0038816&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0038816?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. C. Fitzpatrick & K. Floyd, 2012. "Erratum to Systematic Reviewof the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis," PharmacoEconomics, Springer, vol. 30(1), pages 81-81, January.
    2. Christopher Fitzpatrick & Katherine Floyd, 2012. "A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis," PharmacoEconomics, Springer, vol. 30(1), pages 63-80, January.
    3. Thelma E Tupasi & Rajesh Gupta & Ma Imelda D Quelapio & Ruth B Orillaza & Nona Rachel Mira & Nellie V Mangubat & Virgil Belen & Nida Arnisto & Lualhati Macalintal & Michael Arabit & Jaime Y Lagahid & , 2006. "Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines," PLOS Medicine, Public Library of Science, vol. 3(9), pages 1-10, September.
    4. Zhong-wei Jia & Shi-ming Cheng & Zhi-jun Li & Xin Du & Fei Huang & Xiao-wei Jia & Peng Kong & Yun-xi Liu & Wei Chen & Wei Wang & Christopher Dye, 2010. "Combining Domestic and Foreign Investment to Expand Tuberculosis Control in China," PLOS Medicine, Public Library of Science, vol. 7(11), pages 1-6, November.
    5. Masja Straetemans & Ana L Bierrenbach & Nico Nagelkerke & Philippe Glaziou & Marieke J van der Werf, 2010. "The Effect of Tuberculosis on Mortality in HIV Positive People: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 5(12), pages 1-10, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Senait Alemayehu & Amanuel Yigezu & Damen Hailemariam & Alemayehu Hailu, 2020. "Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-13, July.
    2. Sizulu Moyo & Helen S Cox & Jennifer Hughes & Johnny Daniels & Leigh Synman & Virginia De Azevedo & Amir Shroufi & Vivian Cox & Gilles van Cutsem, 2015. "Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-13, March.
    3. Laura Jean Podewils & Maria Tarcela S Gler & Maria Imelda Quelapio & Michael P Chen, 2013. "Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes," PLOS ONE, Public Library of Science, vol. 8(7), pages 1-8, July.
    4. Marian Loveday & Kristina Wallengren & Tarylee Reddy & Donela Besada & James C M Brust & Anna Voce & Harsha Desai & Jacqueline Ngozo & Zanele Radebe & Iqbal Master & Nesri Padayatchi & Emmanuelle Davi, 2018. "MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care," PLOS ONE, Public Library of Science, vol. 13(4), pages 1-13, April.
    5. Catherine Pitt & Catherine Goodman & Kara Hanson, 2016. "Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 9-28, February.
    6. Jude Beauchamp & Carole D. Mitnick & Hannah Gilbert & Fernet Leandre & Yoldine Talina Jean Noel & Walkens Desir & Christina Lively & Joia Mukherjee, 2021. "Ambulatory Treatment for Multidrug-Resistant Tuberculosis in Rural Haiti: A Mixed-Methods Study of Social and Economic Factors Affecting Timely Diagnosis and Treatment Success," Global Journal of Health Science, Canadian Center of Science and Education, vol. 13(7), pages 1-99, July.
    7. Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2015. "Falsified or Substandard? Assessing Price and Non‐price Signals of Drug Quality," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 24(4), pages 687-711, October.
    8. Juliet N Sekandi & Kevin Dobbin & James Oloya & Alphonse Okwera & Christopher C Whalen & Phaedra S Corso, 2015. "Cost-Effectiveness Analysis of Community Active Case Finding and Household Contact Investigation for Tuberculosis Case Detection in Urban Africa," PLOS ONE, Public Library of Science, vol. 10(2), pages 1-18, February.
    9. Jia Yin & Jinqiu Yuan & Yanhong Hu & Xiaolin Wei, 2016. "Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-14, March.
    10. Guoliang Zhang & Shuqiong Huang & Qionghong Duan & Wen Shu & Yongchun Hou & Shiyu Zhu & Xiaoping Miao & Shaofa Nie & Sheng Wei & Nan Guo & Hua Shan & Yihua Xu, 2013. "Application of a Hybrid Model for Predicting the Incidence of Tuberculosis in Hubei, China," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-1, November.
    11. Benjarin Santatiwongchai & Varit Chantarastapornchit & Thomas Wilkinson & Kittiphong Thiboonboon & Waranya Rattanavipapong & Damian G Walker & Kalipso Chalkidou & Yot Teerawattananon, 2015. "Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-15, May.
    12. Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2012. "Counterfeit or Substandard? Assessing Price and Non-Price Signals of Drug Quality," NBER Working Papers 18073, National Bureau of Economic Research, Inc.
    13. Masja Straetemans & Philippe Glaziou & Ana L Bierrenbach & Charalambos Sismanidis & Marieke J van der Werf, 2011. "Assessing Tuberculosis Case Fatality Ratio: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 6(6), pages 1-1, June.
    14. Yukari C Manabe & Sabine M Hermans & Mohammed Lamorde & Barbara Castelnuovo & C Daniel Mullins & Andreas Kuznik, 2012. "Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-9, June.
    15. Heidi M Soeters & Charles Poole & Monita R Patel & Annelies Van Rie, 2013. "The Effect of Tuberculosis Treatment at Combination Antiretroviral Therapy Initiation on Subsequent Mortality: A Systematic Review and Meta-Analysis," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-1, October.
    16. Lucy Cunnama & Gabriela B. Gomez & Mariana Siapka & Ben Herzel & Jeremy Hill & Angela Kairu & Carol Levin & Dickson Okello & Willyanne DeCormier Plosky & Inés Garcia Baena & Sedona Sweeney & Anna Vass, 2020. "A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cos," PharmacoEconomics, Springer, vol. 38(8), pages 819-837, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0038816. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.